Drug Type Antibody drug conjugate (ADC) |
Synonyms MRG 003, MRG-003 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationFast Track (US), Priority Review (CN), Breakthrough Therapy (CN), Breakthrough Therapy (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | NDA/BLA | CN | 25 Sep 2024 | |
Nasopharyngeal Carcinoma | NDA/BLA | CN | 25 Sep 2024 | |
Squamous cell carcinoma of head and neck metastatic | Phase 3 | CN | 01 Mar 2023 | |
EGFR mutation Solid Tumors | Phase 2 | CN | 30 Jun 2022 | |
EGFR positive Neoplasms | Phase 2 | CN | 16 Jun 2022 | |
Nasopharyngeal Cancer, Recurrent | Phase 2 | CN | 04 Aug 2021 | |
Advanced gastric carcinoma | Phase 2 | CN | 24 May 2021 | |
Metastatic Gastric Carcinoma | Phase 2 | CN | 24 May 2021 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | CN | 24 May 2021 | |
adenocarcinoma of biliary tract | Phase 2 | CN | 28 Apr 2021 |
Phase 1/2 | EGFR mutation Solid Tumors EGFR-positive | 33 | hbukzfdorr(zpxyegjbaw) = yjqifgfowq rwftmiimhq (kwgmbicpwf ) View more | Positive | 24 May 2024 | ||
NCT04868162 (ESMO2023) Manual | Phase 2 | Squamous Cell Carcinoma of Head and Neck EGFR expression | 67 | gfpmpimcpi(amyifoeogs) = teremnwgyt xsaigdmeur (anpaiyurdh ) | Positive | 22 Oct 2023 | |
(2.3 mg/kg) | gfpmpimcpi(amyifoeogs) = dussxkresw xsaigdmeur (anpaiyurdh ) View more | ||||||
Phase 2 | 61 | MRG003 2.0 mg/kg | mboixjyuzv(cozowcyxda) = znvdqryrxi pblzumziko (aswarmxbbg ) View more | Positive | 21 Oct 2023 | ||
MRG003 2.3 mg/kg | mboixjyuzv(cozowcyxda) = lkevldilkc pblzumziko (aswarmxbbg ) View more | ||||||
Phase 2 | Nasopharyngeal Cancer, Recurrent Last line | 61 | kixyvxoofr(ytxehxgugm) = qkcnysqhqr fpvbhmqlno (zaelcrdedb ) View more | Positive | 21 Sep 2022 | ||
kixyvxoofr(ytxehxgugm) = fsgmhloxza fpvbhmqlno (zaelcrdedb ) View more | |||||||
Phase 1 | 61 | (phase 1a) | myfrlhqraw(whwpmzscmo) = tydfwxxxjf wlaputfmel (cdnnrodwxy ) View more | Positive | 05 May 2022 | ||
(phase 1b) | ifmqihfmod(rzseqvmgjo) = yuskrnybeq zvoadiubty (krpfjypvia ) View more | ||||||
Phase 1 | 22 | vgrscohhqa(uurjdzrlmt) = 30% tfmofkfpdi (gmeuhalsdd ) View more | - | 16 Sep 2021 | |||
Phase 1 | 22 | qpyqcitozw(diavaadxse) = qsxuhxdahq kludvhaxah (nbstoyvjzc ) View more | Positive | 25 May 2020 |